Table 3. Multivariate analyses identified gene- and exon-based signatures as independent prognostic markers for OS.
| P -value | odds ratio | 95% Confidence interval | ||
|---|---|---|---|---|
| Age | 0.42 | 2.2 | 0.3 | 18.9 |
| MNA | 0.36 | 1.9 | 0.5 | 8.1 |
| TrkA | 0.42 | 2.8 | 0.3 | 64.8 |
| INSS stage IV | 0.10 | 3.3 | 0.8 | 14.4 |
| Exon signature | 0.006 | 10.7 | 2.2 | 71.0 |
| Age | 0.33 | 2.6 | 0.4 | 21.8 |
| MNA | 0.31 | 2.1 | 0.5 | 8.5 |
| TrkA | 0.39 | 2.9 | 0.3 | 66.9 |
| INSS stage IV | 0.09 | 3.4 | 0.9 | 14.8 |
| Gene signature | 0.007 | 9.7 | 2.1 | 61.3 |
Abbreviations: INSS=International Neuroblastoma Staging System; OS=overall survival.
Predictive power of mRNA-based signatures were compared with age at diagnosis (age, < or >12 months at diagnosis), MYCN status (MNA, MYCN amplified vs MYCN single copy), INSS stage (INSS, stage IV vs non-stage IV) or NTRK1 expression (TrkA, NTRK1 expression < or > median). Odds ratios and 95% confidence intervals are presented.